VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended June 30, 2015. Recent key corporate and clinical developments include: Reported record patient enrollment numbers in April with 31 patients, 26 patients in May and 25 patients in June in the Phase 3 head and neck cancer trial. A total of five hundred twenty one (521) patients have been enrolled in the Phase 3 study as of July 31, 2015 after new record patient enrollment of 33
| < Prev | Next > |
|---|
